Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Cetuximab & Head & Neck squamous cell carcinoma (HNSCC), the FDA has approved cetuximab as monotherapy for recurrent or metastatic Head & Neck squamous cell carcinoma (HNSCC) after failure of platinum‑based chemotherapy (1, 2).
The EMA has also approved cetuximab for recurrent or metastatic Head & Neck squamous cell carcinoma (HNSCC) as monotherapy (2, 3).
(1) [FDA approves cetuximab with platinum-based therapy plus 5-FU for first-line treatment of SCCHN - ecancer](https://ecancer.org/en/news/2136-fda…